Skip to main content

Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point

Biotechnology sector-related exchange traded funds were in a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS: TPTX). Among the best performing non-leveraged ETFs of Friday, the SPDR S&P Biotech ETF...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.